Preface – Preceptorship Cologne
Dear Colleagues,
This report summarizes presentations that were given during the Lung Cancer International Preceptorship Conference that took place in Cologne, Germany, on February 1 and 2, 2018. The University Hospital of Cologne and the Center for Integrated Oncology Köln-Bonn jointly organized this conference, which was addressed to medical oncologists involved in the care of patients with lung cancer. This was not just an interdisciplinary exchange of experience of specialists from different Departments of the University Hospital and the Lung Cancer Group of Cologne through lectures and discussions on scientific and clinical topics, as the participants also had the opportunity to gain some practical insight during guided tours through the Molecular Pathology Unit, the Cyberknife Department and the Interdisciplinary Outpatient Clinic. In addition, in parallel, workshop participants could learn how to design trials on topics like EGFR TKI resistance, immunotherapy, brain metastases, and neoadjuvant therapy.
The lectures were organized in different sections with a strong focus on diagnostics and treatment of the different stages of non–small-cell lung cancer (NSCLC). Molecular pathology was a particularly important topic across almost all aspects of the program. In recent years, a multitude of studies has provided us with a range of innovative therapies, the application of which demands algorithms that support physicians in the shaping of their treatment decisions. Molecular pathology therefore has developed into a kind of gatekeeper in this process of designing therapeutic strategies for these patients. We hope that this summary of the Preceptorship will provide physicians with better understanding of the challenges linked to the care of patients with lung cancer.
Jürgen Wolf, MD, University Hospital of Cologne
More posts
New therapeutic options being currently investigated in advanced or metastatic colorectal cancer
Colorectal cancer (CRC) is the second leading cause of cancer death in the United States, and it is the fourth most frequent cancer diagnosis.A current treatment option for RAS and BRAF wild-type (WT) metastatic colorectal cancer (mCRC) is the chemotherapy doublet (FOLFOX/FOLFIRI) with an anti-EGFR monoclonal antibody (cetuximab or panitumumab).
An update and future directions in advanced gastric or gastrointestinal junction cancer (G/GEJC)
With more than 1 million newly diagnosed cases in 2020, gastric cancer (GC) is the fifth most frequent cancer; it was also the third leading cause of cancer-related death worldwide. Gastroesophageal junction (GEJ) cancer concerns a form of gastric cancer developing around the digestive tract where esophagus and stomach connect; in the last years, the prevalence of GEJ constantly increased.
Innovative combinations in esophageal squamous cell carcinoma
Each year, esophageal cancer (EC) is responsible for more than half a million deaths worldwide. Among them, esophageal squamous cell carcinoma (ESCC) accounts for the vast majority (~ 85 %) of EC incidences . At diagnosis, 70 % of ESCC is unresectable [3] and the 5-year survival rate is limited (30 % - 40 %). Patients with advanced or metastatic ESCC have a poor prognosis; their overall survival (OS) after standard first-line chemotherapy is limited to less than a year and other treatment options are scarce.
Novel agents or combinations in recurrent or metastatic nasopharyngeal cancer
Nasopharyngeal cancer (NPC) is a rare malignancy with an incidence of approximately 133,000 annually worldwide, resulting in about 80,000 deaths per year. Whereas early-stage and locally advanced NPC have a good prognosis, treatment of recurrent or metastatic nasopharyngeal cancer is a challenging; it is thus associated with a poor prognosis, especially in patients who have failed two or more lines of systemic therapy, with a median progression-free survival (mPFS) of seven months and median overall survival (mOS) of 22 months.
Preface ASCO Solid Tumor 2022
After 2 years of the COVID-19 pandemic, the Annual Meeting of the American Society of Clinical Oncology (ASCO), was held in Chicago, USA, and virtually from 3rd–7th June 2022.As always, the very much-anticipated event brought leading experts from across the globe together to learn and discuss the groundbreaking updates and scientific advancements which were covered in more than 2,000 abstracts, along with 85 livestream sessions, and more than 2,500 poster presentations.